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Protoporphyria is an inherited disorder in man characterized by theoverproduction ofprotoporphyrin, a
compound that is excreted by the liver. Hepatobiliary disease may occur in protoporphyria, and several cases
have been reported in which death was due to liver disease. Based on the histological evaluation of liver
biopsy specimens from 18 patients, 6 of whom died with cirrhosis and liver failure, we speculate that liver
disease in this condition is caused byprotoporphyrin deposits inhepatobiliary structures. Thesedeposits are
composed of crystals and have a characteristic birefringence when examined by polarization microscopy.
One patient with early liver damage was given cholestyramine and vitamin E in an attempt to reduce the
amount of protoporphyrin which the liver excreted daily. Liver function tests returned to normal, and red
cell and plasma protoporphyrin levels decreased. A repeat liver biopsy after one year of therapy showed
healing, with decrease of the protoporphyrin deposits.
Liver disease in protoporphyria may be treated by directing therapy toward the metabolic abnormality.
INTRODUCTION
Protoporphyria is an inherited disorder ofporphyrin metabolism in man in which
there are increased levels ofprotoporphyrin in red cells, plasma, and feces. Protopor-
phyrin is a dicarboxylic acid porphyrin that is poorly water-soluble at physiological
pH. It is excreted solely into bile [1]. Urinary excretion of protoporphyrin does not
occur, even in the face of biliary obstruction.
Recent studies have demonstrated that the basic defect in protoporphyria is a
deficiency in the activity of heme synthetase (ferrochelatase), the enzyme which
catalyzes the chelation of iron to protoporphyrin to form heme (Fig. 1). Deficient
heme synthetase activity has been demonstrated in various tissues from patients with
protoporphyria, including liver [2-6]. Although the developing red cell is probably
the major site of porphyrin overproduction in the disease [7], studies with labeled
precursors of protoporphyrin indicate that the liver may contribute a variable
fraction [8,9].
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FIG. 1. Heme biosynthetic pathway. In protoporphyria, the basic defect is a deficiency of heme synthetase activity,
which catalyzes chelation ofiron to protoporphyrin to form heme. This leads to excessive accumulation and excretion of
protoporphyrin.
Photosensitivity, with onset in early childhood, is the major clinical manifestation
of the disease. It is produced when protoporphyrin absorbs light of wavelength
400-410 nm and initiates damage in skin. Hepatobiliary disease is less common but
may be a critical complication, and 15 deaths from hepaticfailure have been reported
[10-22]. These cases are summarized in Table 1. The patients have generally been
over the age of 30. Cripps and coworkers recently reported the youngest case offatal
liver disease in an 11-year-old boy with protoporphyria [21]. Porter and Lowe
previously reported a 6-year-old boy with protoporphyria and cirrhosis who im-
proved following splenectomy [23]. Thus liver disease is less common in younger
patients, but certainly occurs.
The clinical histories of the patients indicated that the liver disease was not
associated with alcoholism, viral hepatitis, drug use, or exposure totoxins. Biochemi-
cal studies showed direct hyperbilirubinemia (total levels 7.0 to 22.0 mg/ 100 ml),
mild to moderate increases in the serum transaminase (60 to 475 units), and less than
twofold elevations in the serum alkaline phosphatase. Hepatitis B infection, a 1-
antitrypsin deficiency, iron overload, and chronic active hepatitis associated with
smooth muscle antibody were excluded in those patients in whom studies were
performed.
Liver biopsy specimens from the fatal cases demonstrated cirrhosis with massive
deposits of dark brown pigment. When examined by polarizing microscopy, the
pigment deposits were found to have a distinctive birefringence [24], and on electron
microscopy, were shown to be crystalline in nature [17]. Although the chemical
composition of the birefringent pigment deposits has not been completely defined,
they are thought to be composed in major part of protoporphyrin, since the
protoporphyrin content of the liver specimens has been very high(Table 1). Thus the
current speculation is that liver disease occurs in protoporphyria because protopor-
phyrin deposition in hepatobiliary structures causes hepatic inflammation and
fibrosis.
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TABLE I
Cases of Protoporphyria Dying with Cirrhosis and Hepatic Failure
Hepatic Pigment
Patient Protoporphyrin Levels Deposits
Liver
Red cell Plasma (ug/g Birefrin-
Author and Yeara Age Sex (pg/ 100 ml) (p,g/ 100 ml) wet wt.) Present gent
Barnes et al. (1968) 42 M - - 4900 + NEb
Donaldson et al. (1971) 56 M 6000 - 208 + NE
58 M - - - + NE
Schmidt and Stich (1971) 40 F 3150 - 760 + NE
Iwanov et al. (1972) 42 M 3793 - - + NE
Scott et al. (1973) 43 F 4000 690 3200 + NE
Thompson et al. (1973) 31 F - - - + +
31 F 2000 - - + +
Meffert et al. (1974) 44 F 3180 - - + NE
Bloomer et al. (1975) 33 F 4516 790 1787 + +
Meyer et al. (1975) 16 M 7749 - - + +
Pimstone et al. (1976) 29 M - - 1600 + +
Nicholson and
Zawirska (1976) 55 M 4700 - 819 + NE
Cripps et al. (1977) 11 M 8700 870 57,500 + +
Singer et al. (1978) 60 M 3170 56 - + +
Normal levels <50 <10 trace
aYear of report. See references [10-22] for individual cases.
bNE Hepatic pigment deposits were not examined for birefringence.
These observations indicate that the liver plays a central role in protoporphyria.
The following report summarizes the experience in the Yale Liver Study Unit with
hepatic aspects of the disease.
RESULTS
Histological Features ofLiver Biopsy Specimens in Protoporphyria
Liver biopsy specimens were examined from 18 patients with protoporphyria, 6 of
whom died in hepaticfailure with cirrhosis. All ofthefatal cases have beenpreviously
reported [15,17,18,19,22]. Biopsy specimens from 5 of the 12 nonfatal cases were
supplied by Dr. Derek Cripps ofthe University ofWisconsin and Dr. Peter.Scheuer
of the Royal Free Hospital, London [25]. In each case, the diagnosis of protopor-
phyria was made on the basis of life-long photosensitivity and elevated red cell
protoporphyrin levels. Several of the patients had other family members with the
disease.
Cirrhosis was present in each of the fatal cases. In addition, there was active
hepatocellular necrosis, portal inflammation, and cholestasis. Characteristically,
there were massive deposits of dark brown pigment in Kupffer cells, portal histio-
cytes, bile canaliculi, and parenchymal cytoplasm (Fig. 2). When examined by
polarization microscopy, the pigment deposits showed striking birefringence(Fig. 2).
Large deposits were bright red with a central dark Maltese cross, whereas the smaller
deposits appeared as clusters ofbrilliantly illuminated granules. Ultrastructurally, the
deposits were composed ofcrystalline material which lay free in the cytoplasm ofthe
hepatocytes, but in Kupffer cells were exclusively in lysosomes (Fig. 2).
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FIG. 2. Hepatic protoporphyrin deposition in a case of protoporphyria with cirrhosis and fatal hepatic failure. Top
left: Diffuse pigment deposits in parenchyma. Hematoxylin and eosin stain. Top right: Polarization microscopy of
pigment deposits showing birefringence with centrally located dark Maltese crosses. Hematoxylin and eosin stain.
Bottom left: Part of one hepatocyte contains a star-burst deposit made up of amorphous material and electron-dense
crystals arranged radially. Lead hydroxide stain. Bottom right: Several crystals are shown within the lysosomes of a
Kupffer cell. Lead hydroxide stain. Reprinted with the permission ofThe American Journal ofMedicine (Bloomer et al,
Am J Med 58:869-882, 1975).
Needle liver biopsy specimens were also examined from 12 nonfatal cases (Table
2). These cases were not randomly selected and do not indicate the frequency with
which hepatic lesions will be found in patients with protoporphyria at large.
Birefringent pigment deposits were present in 7 ofthe cases. The deposits were found
in portal triads, and there was portal inflammation with a variable degree offibrosis.
In 4 of the 7 cases, there was also parenchymal pigment deposition accompanied by
hepatocellular necrosis. None ofthe cases without birefringent pigment deposits had
hepatocellular necrosis. However, 2 showed portal inflammation and fibrosis.
There was no evidence of iron overload in any ofthe 18 patients, as evaluated by
iron stains of the liver biopsy specimens.
TABLE 2
Lesions in Needle Liver Biopsy Specimens of Patients with Nonfatal Protoporphyria
Birefringent pigment Birefringent pigment
deposits present deposits absent
(7 cases) (5 cases)
Portal inflammation 7 2
± fibrosis
Hepatocellular necrosis 4 0
Cirrhosis 0 0
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TABLE 3
Hepatic Heme Synthetase (HSyn) and 8-aminolevulinic Acid Synthetase (ALAS) Activities in Protoporphyria
Liver HSyn ALAS
Case Histology (pmoles heme/mg protein/hr) (pmoles ALA/mg protein/hr)
I Normal 508
2 Normal 906
3 Portal inflammation 440
4 Portal inflammation 297 853
5 Cirrhosis 91 -
Meani SEM 448 i 135
Controls (mean i SEM) 2078 ± 298a 476 i 70b
a10 patients b6 patients
Hepatic Heme Synthetase and ALA Synthetase Activities in Protoporphyria
Heme synthetase activity was measured by a radiochemical assay[5] inliverbiopsy
specimens from 5 patients with protoporphyria (Table 3). The mean activity was
significantly reduced compared to that in 10 control biopsy specimens with similar
degrees of hepatocellular damage (p < 0.001).
The activity of ALA synthetase, the first and rate-limiting enzyme of the heme
biosynthetic pathway, was measured by a radiochemical assay [26,27] in the liver
biopsy specimen of one patient with protoporphyria. It was mildly increased
compared to that in 6 control specimens (Table 3).
Therapy ofHepatic Disease in Protoporphyria
Serial observations in one patient have provided the opportunity to evaluate
whether hepatic disease in protoporphyria can be reversed. The result of the initial
evaluation of this patient, as well as that of her 33-year-old sister who died with
protoporphyria and liver failure, has previously been published[17]. Her case history
is as follows:
This 26-year-old housewife had severe photosensitivity since childhood. She never
had signs or symptoms of hepatobiliary disease. She had one uncomplicated
pregnancy, delivering a healthy female child. The patient did not drink alcoholic
beverages. She had taken birth control pills (Ovral) but did not use other medicines.
During that period her photosensitivity did not worsen. The birth control pills were
stopped one week before her admission to Yale-New Haven Hospital.
Physical examination was normal, except for mild scarring over the lips and
thickening ofthe skin over the dorsal aspects of her hands and forearms. Therewere
no stigmata of liver disease. The serum glutamic oxaloacetic transaminase (SGOT)
level was 69 units (normal less than 35), and bromosulfalein (BSP) retention at 45
min was 12% (normal less than 5%). The serum bilirubin was 0.86 mg/ 100 ml,
alkaline phosphatase 50 IU/L, cholesterol 195 mg/ 100 ml, and albumin/globulin
4.4/3.1 g/ 100 ml (all normal). Hematological values were normal. Serum iron was 92
,g! 100 ml, with a total iron binding capacity of 496,ig/ 100 ml. The serum did not
contain hepatitis B antigen or antibody, smooth. muscle antibody, or mitochondrial
antibody. Oral cholecystogram was normal. Liver scanwith technetium sulfurcolloid
showed hepato-splenomegaly without focal defects. The protoporphyrin concentra-
tions in her red cells and plasma were 1426 + 212 ug/ 100 ml red cells and 123 ± 46
,ug/ 100 ml plasma (mean ± SEM of 5 fasting blood samples) (normal less than 50
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pg/ 100 ml red cells and 10 yg/ml plasma). Fecal excretion ofprotoporphyrin was 38
mg/24 hr in a 72 hr stool specimen (normal less than 4 mg/24 hr).
Needle liver biopsy revealed normal lobular architecture, but all portal triads were
enlarged with occasional fibrous bridging. The triads showed erosion of the limiting
plates and contained a variable number of lymphocytes, pigmented macrophages,
and globules of brown pigment. Central zones showed focal loss of hepatocytes
which were replaced by collections of pigmented macrophages and lymphocytes.
Rare canaliculi contained pigment deposits as well. When examined by polarization
microscopy, the pigment deposits showed birefringence. None of the hepatocytes
examined by electron microscopy contained crystalline deposits. However, the
lysosomes were prominent. Numerous crystalline deposits were observed in lyso-
somes within Kupffer cells. Iron stain of the liver revealed normal iron stores.
The patient was started on cholestyramine (12 g/day ofQuestran in divided doses)
and vitamin E(100 units ofAquasol E daily). The first period oftherapy extended for
11 months (Fig. 3). Her plasma protoporphyrin concentraion fell rapidly after
starting therapy. The mean concentration duringthe period oftherapy was 16 ,ug/ 100
ml, only 13% of the pre-therapy value, and the majority of levels were normal. The
red cell concentration diminished at a slower rate than the plasma level. By the end of
therapy the level was only 30% of the pre-therapy value. Fecal excretion of
protoporphyrin similarly declined.
The serum transminase and BSP retention returned to normal during this period.
There was no change in the patient's serum iron level or hematological values. Her
photosensitivity was dramatically decreased.
Needle liver biopsy at the end ofthis period showed that several portal triads still
had scarring and increased numbers of ductules and pigmented histiocytes. Some
central areas had zones of collapse. However, there was a marked decrease in the
amount of necrosis, inflammation, and fibrosis compared to the pre-therapy biopsy.














Cumulative Mo$ 0 6 12 18 24 30 36 42 48 54 60 66
Mo/year 8/72 8/73 8/74 8/75 8/76 8/77
FIG. 3. Course in a patient with protoporphyria who was treated with cholestryamine (12 g Questran daily) and
vitamin E (100 units Aquasol E daily) because ofhepatic damage. In addition, Beta-carotene was given on two occasions
to treat photosensitivity. See text and Fig. 4 for effects of therapy on liver function tests and liver histology.
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FIG. 4. Pre-therapy liver biopsy specimen of patient in Fig. 4 is compared with that after the first year of therapy.
Left: Part of one Kupffer cell in the pre-therapy biopsy specimen shows lysosomal granules stuffed with amorphous
material, electron dense droplets, and numerous elongated crystals. Lead hydroxide stain. Right: Part of several Kupffer
cells is shown in the post-therapy liver biopsy specimen. Crystalline material is absent. Lead hydroxide stain.
copy was considerably less. The hepatocytes appeared ultrastructurally normal. The
prominent hepatocellular lysosomes seen previously were now reduced to normal
size. The Kupffer cells were also normal, and crystalline deposits were not found in
their lysosomes (Fig. 4).
When the patient was withdrawn from therapy for 3 months, there was a steady
increase in the red cell protoporphyrin level, with a lesser increase in the plasma level
(Fig. 3). She was subsequently restarted on therapy. Liver function tests have
continued to be normal for the remainder of her course. Liver biopsy has not been
repeated.
DISCUSSION
Protoporphyrin is formed by sequential decarboxylation of the porphyrin side
chains (Fig. 1). Uroporphyrin, which has 8 carboxyl groups, is converted to
protoporphyrin, which has 2 carboxyl groups, causing the molecule to be less water
soluble and changings its route ofexcretion. Uroporphyrin is excreted predominantly
in urine, coproporphyrin in both urine and bile, and protoporphyrin solely in bile[1].
The mechanism by which hepatic excretion of protoporphyrin occurs has not been
defined. Part of the excretory pathway may be the same as that for other organic
anions such as bilirubin. Protoporphyrin is not changed to a more polarderivative by
hepatic metabolism, however.
In protoporphyria, protoporphyrin accumulates in excessive amounts because of
the reduced activity of heme synthetase. Erythropoietic tissue appears to contribute
the major fraction. Free protoporphyrin rapidly leaves newly formed red cells when
they enter the circulation and may account for the protoporphyrin which is excreted
in stool [7]. Since heme synthetase activity is deficient in hepatic tissue of patients
with protoporphyria (Table 3), the liver may also contribute to protoporphyrin
accumulation. This possibility is supported by studies which have utilized labeled
precursors of protoporphyrin [8,9], although the interpretation of these studies is
controversial [28].
Regardless ofthe sites ofprotoporphyrin accumulation, the liver must excrete the
excess amount. Liver damage may occur when crystalline protoporphyrin deposits
form in hepatobiliary structures. Cholelithiasis has been reported in patients with
protoporphyria [25,29], and the gallstones have contained high levels of protopor-
phyrin. Protoporphyrin also precipitates in intrahepatic bile ducts and bile canaliculi.
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Either extrahepatic orintrahepatic biliary precipitation ofthe compound could cause
portal inflammation and fibrosis by biliary obstruction or by a toxic effect of the
crystalline material on bile duct epithelium. Crystalline deposits of protoporphyrin
also form within hepatocytes (Fig. 2), a process which may cause cell death. As liver
damage is initiated and cholestasis develops, protoporphyrin accumulation in the
liver may increase rapidly. The common history ofpatients with protoporphyria who
have died in liver failure is that death occurred within afew months afterthe onset of
jaundice.
Since significant liver disease occurs in a small percentage of patients with
protoporphyria, it is important to identify susceptible individuals. Liver function
tests may be minimally abnormal in patients in whom the fatal cycle is imminent
[10-22]. Fecal protoporphyrin excretion has not been correlated with the potential to
develop liver damage, but red cell protoporphyrin levels have been very high in
patients who have died with cirrhosis and liver failure (Table 1). This may reflect the
fact that protoporphyrin is in a dynamic flux between red cell, plasma, and liver
compartments. In the animal in which experimental porphyria has been produced,
red cell protoporphyrin levels increase linearly after the hepatic concentration
reaches 100 ,ug/g wet weight [30], a level which is much lower than that found in
patients with fatal protoporphyria (Table 1). For these reasons, liver biopsy is
indicated to evaluate patients with protoporphyria who have abnormal liverfunction
tests, even of minimal degree, and markedly elevated red cell and plasma protopor-
phyrin levels.
Therapy of.hepatic disease in protoporphyria should be directed at depleting
hepatic porphyrin stores and diminishing the amount of protoporphyrin which the
liver has to excrete. One approach is to decrease the rate of protoporphyrin
production. Factors which may adversely affect heme synthetase activity, such as
iron deficiency [31], should be corrected. Fasting should be avoided [14], since
measurements of fecal pretoporphyrin excretion suggest that protoporphyrin pro-
duction increases during caloric restriction [32]. Infusion of hematin, which dimin-
ishes levels of porphyrin precursors in urine and blood of patients with acute
intermittent porphyria by negative feedback repression of ALA synthetase [33], may
decrease protoporphyrin overproduction in protoporphyria[34]. Vitamin E adminis-
tration has also been proposed as a means by which to diminish porphyrin
production in porphyric disorders [35], although studies of its effect have produced
inconsistent results [36,37].
A second line of therapy is to interrupt the enterohepatic circulation of protopor-
phyrin [38] by administering cholestyramine, a nonabsorbable compound which
binds anionic compounds [39]. Kniffen [40] and Lischner [41] reported that choles-
tyramine therapy reversed hepatic disease in patients with protoporphyria.
Therapy with cholestyramine and aqueous vitamin E was associated with signifi-
cant improvement in our patient. Protoporphyrin levels decreased (Fig. 3), liver
function tests returned to normal, and the hepatic lesion resolved (Fig. 4). However,
caution must be used in attributing theimprovement entirely to the administration of
these compounds. It is conceivable that she had spontaneous improvement, although
the pattern of her response to therapy makes this unlikely. Second, she had been
taking birth control pills fortwo years before herinitial evaluation. Birth control pills
do not produce the hepatic lesion which was present in her biopsy specimen but they
might impair the hepatic excretion of protoporphyrin, thereby contributing to the
hepatic damage indirectly.
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The fact that protoporphyrin levels in red cells, plasma, and liverofourpatient all
diminished during therapy indicates there was an overall decreaseintissue porphyrin
stores. It is not possible to evaluate the relative contributions of enhanced protopor-
phyrin excretion and decreased protoporphyrin production tothis change. However,
the observations do indicate that excretion of protoporphyrin was greater than the
rate of production during this period.
This patient's course demonstrates that hepatic damage in protoporphyria may be
reversed if detected at an early stage. Improvement was associated with adecrease in
hepatic pigment deposits, lending further support to the concept that liver disease in
protoporphyria is caused by the deposition of protoporphyrin in hepatobiliary
structures.
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